Optional product analytics
With your permission, we use privacy-limited analytics to understand which research journeys work. We do not run advertising trackers or session replay. You can change this choice in Preferences. Read the Privacy Policy.
Massive installed base of da Vinci systems
Medtronic/J&J Capture 30% Market Share: Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder.
Intuitive Surgical maintains a dominant, near-monopoly position in soft-tissue robotic surgery. Its massive installed base of da Vinci systems creates a razor-and-blade model with high switching costs, generating robust recurring revenues from instruments and accessories. Strong free cash flow generation and high ROIC solidify its status as a premier quality compounder.
Massive installed base of da Vinci systems
High switching costs for hospitals and surgeons
Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.
Sell. Exceptional business quality is entirely overshadowed by extreme overvaluation.
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. It offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. The company also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of customer service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. It sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
A severe hospital capex freeze combined with accelerated placements of competing systems like Medtronic's Hugo compresses margins and slows new system placements significantly.
Massive installed base of da Vinci systems
High switching costs for hospitals and surgeons
Recurring razor-and-blade instrument revenue
Economic profit is supported when reported returns exceed the company cost-of-capital hurdle.
Unavailable
FCFF DCF remains positive at the base case: base FCFF $2.7B after capex $503.2M, with terminal value at 59.3% of enterprise value. No FCF cliff is projected unless capex/ or materially resets.
If procedure volumes exceed 15% growth, target $327 forward earnings base. If system placements stall, default to $210 intrinsic moat fade base.
If procedure volumes exceed 15% growth, target $327 forward earnings base. If system placements stall, default to $210 intrinsic moat fade base.
If procedure volumes exceed 15% growth, target $327 forward earnings base. If system placements stall, default to $210 intrinsic moat fade base.
Heavy initial R&D and SG&A phases transition into high-ROIC, low-capex cash generation.
Post-pandemic procedure backlog clearance drives elevated system utilization and instrument consumption.
Hospital budget constraints delay capital equipment purchases; procedure volumes normalize to long-term averages.
Heavy initial R&D and SG&A phases transition into high-ROIC, low-capex cash generation.
Avoid or maintain zero weight. The current $450 price embeds a massive premium that leaves no margin of safety.
If currently holding, aggressively trim or exit the position given the -43% downside to intrinsic value.
Upside case depends on the report valuation range and named growth catalysts.
While ISRG is a premier quality compounder with a wide moat, the market is pricing in flawless hyper-growth indefinitely. Intrinsic models conservatively suggest extreme overvaluation.
Sell. The 56% divergence from internal valuation cross-checks signals heavy market premium; intrinsic baseline valuation is $254.67.
Reassess the thesis against the named valuation, risk, and quarterly checkpoint evidence in this report.
Capture your own thesis, position size, and follow-up questions. Stays on this device, only you can see it.
Competitive incursions and budget constraints severely slow placements and compress the multiple to historical lows.
Competitors successfully disrupt the monopoly, forcing severe pricing pressure on systems and instruments.
Macro-driven hospital budget cuts drastically slow new system placements and upgrade cycles globally.
Emergence of non-robotic, highly effective minimally invasive alternatives permanently reduces TAM for da Vinci.
The five developments that would weaken our investment case.
A sharp slowdown in overall top-line expansion reflects decelerating robotic surgical adoption and procedure volume growth in mature hospital networks, eroding the high-margin recurring revenue stream generated by instrument and accessory sales.
Current:20.5% for the period ended 2025-12-31
Alert ifRevenue growth drops below 10.0% for any fiscal year
Erosion of gross margins indicates that pricing pressure on surgical systems and instruments or rising manufacturing costs are undermining unit economics, significantly impairing operating leverage and free cash flow generation.
Current:66.0% for the period ended 2025-12-31
Alert ifGross margin falls below 60.0% for any fiscal year
Stalling robotic capital equipment placements and extended hospital procurement cycles reduce high-margin hardware sales, compressing operating profitability and limiting the expansion of the global installed base that drives recurring instrument demand.
Current:29.3% for the period ended 2025-12-31
Alert ifOperating margin falls below 24.0% for any fiscal year
Market share losses to competing robotic surgery platforms with superior clinical outcomes or aggressive pricing destroy the company's competitive moat, lowering returns on capital and degrading long-term terminal growth expectations.
Current:13.0% as of the report's 2026-05-09 analysis date
Alert ifROIC declines below 10.0% as of any annual measurement date
Persistent divergence between operating cash flows and net income indicates aggressive revenue recognition or expanding unpaid customer receivables, undermining reported earnings quality and forcing management to lower forward earnings projections.
Current:1.061 as of the report's 2026-05-09 analysis date
Alert ifOperating cash flow to falls below 0.85 over any trailing twelve-month period
Each lens answers a different valuation question. Only included lenses set Fair value; floors and diagnostics provide context.
Project SBC-adjusted EPS, discount each year's earnings at cost of equity, then add a Gordon-growth terminal value.
Project EPS through the explicit advantage period, fade growth as competition catches up, and discount the full stream at cost of equity.
Apply a terminal P/E to the dated forward EPS path, then discount that future share value back to the analysis date.
Convert the revenue and margin path into after-tax free cash flow, discount the annual per-share amounts and at , then adjust for signed per current share.
Add depreciation to net income, subtract maintenance capex, divide by diluted shares, and apply a normalized valuation multiple.
Multiply the peer median PEG by this stock's forecast growth to derive an implied forward P/E, then apply it to forward EPS.
Solve for the growth rate that makes the model value equal the report-date share price.
Growth naturally fades to GDP over a standard 10-year horizon, anchoring intrinsic value to a 25x multiple as maturity is reached.
Warning level: Revenue growth drops below 10.0% for any fiscal year. A sharp slowdown in overall top-line expansion reflects decelerating robotic surgical adoption and procedure volume growth in mature hospital networks, eroding the high-margin recurring revenue stream generated by instrument and accessory sales.
Warning level: Gross margin falls below 60.0% for any fiscal year. Erosion of gross margins indicates that pricing pressure on surgical systems and instruments or rising manufacturing costs are undermining unit economics, significantly impairing operating leverage and free cash flow generation.
Warning level: Operating margin falls below 24.0% for any fiscal year. Stalling robotic capital equipment placements and extended hospital procurement cycles reduce high-margin hardware sales, compressing operating profitability and limiting the expansion of the global installed base that drives recurring instrument demand.
Warning level: ROIC declines below 10.0% as of any annual measurement date. Market share losses to competing robotic surgery platforms with superior clinical outcomes or aggressive pricing destroy the company's competitive moat, lowering returns on capital and degrading long-term terminal growth expectations.
Warning level: Operating cash flow to net income falls below 0.85 over any trailing twelve-month period. Persistent divergence between operating cash flows and net income indicates aggressive revenue recognition or expanding unpaid customer receivables, undermining reported earnings quality and forcing management to lower forward earnings projections.
| $7.12B |
| $8.35B |
| $10.06B |
| +17.4% |
| Gross profit | $4.20B | $4.73B | $5.63B | $6.64B | +16.5% |
| Operating income | $1.58B | $1.77B | $2.35B | $2.95B | +23.1% |
| Net income | — | — | — | — | — |
| EPS (diluted) | $3.65 | $5.03 | $6.42 | $7.87 | +29.2% |
| EBITDA | $1.94B | $2.22B | $2.85B | $3.62B | +23.1% |
| R&D | $879.0M | $998.8M | $1.15B | $1.31B | +14.3% |
| SG&A | $1.74B | $1.96B | $2.14B | $2.39B | +11.1% |
Capital allocation should be evaluated against reinvestment needs, balance-sheet strength, and shareholder returns.
| Total assets | 20,458,700,000 |
|---|---|
| Cash | 3,368,000,000 |
| Current assets | 9,779,500,000 |
| Total liabilities | 2,517,000,000 |
| Current liabilities | 2,006,200,000 |
| Shareholders’ equity | 17,824,000,000 |
Point-in-time financial data used in the 2026-05-09 analysis.
| Period | Revenue | EBITDA | Net income | Operating cash flow | Free cash flow | Capex | Depreciation and amortization | Stock-based compensation | Share repurchases | Dividends paid | Net debt issuance | Investing cash flow | Financing cash flow | Beginning cash | Ending cash | Cash and investments | Total debt | Operating margin | ROIC | WACC | ROIC − WACC spread |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021-12-31 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 87M | — | — | — | — |
| 2022-12-31 | 6.2B | 1.9B | — | 1.5B | 958.4M | 532.4M | 365.8M | 513.2M | 2.6B | — | — | — | — | — | — | 1.6B | — | 25.3% | — | — | — |
| 2023-12-31 | 7.1B | 2.2B | — | 1.8B | 749.6M | 1.1B | 454.8M | 592.8M | 416.3M | — | — | — | — | — | — | 2.8B | — | 24.8% | — | — | — |
| 2024-12-31 | 8.4B | 2.8B | — | 2.4B | 1.3B | 1.1B | 499.7M | 676.8M | 0 | — | — | — | — | — | — | 2B | — | 28.1% | — | — | — |
| 2025-12-31 | 10.1B | 3.6B | — | 3B | 2.5B | 539.8M | 677.1M | 788.2M | 2.3B | — | — | — | — | — | — | 3.4B | — | 29.3% | — | — | — |
ISRG trades at 38.2x forward earnings against a peer median of 15.6x; EV/EBITDA of 39.9x against a peer median of 13.8x; 6 peers.
| Wait for a severe market dislocation or earnings miss that drives the price closer to the $254 mid-point fair value. |
| ResMed Inc. |
| 17.0x |
| 5.4x |
| 13.8x |
| 25.2% |
| 35.3% |
| WST | West Pharmaceutical Services Inc. | 34.1x | 7.1x | 26.2x | 19.1% | 21.7% |
| HOLX | Hologic Inc. | 15.6x | 4.1x | 12.7x | 10.9% | 23.0% |
| SOLV | Solventum Corporation | 10.4x | 1.5x | 15.5x | 34.8% | 5.6% |
